CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC) today announced plans to
present new data for multiple research- and clinical-stage programs
across the company's precision oncology and hematology portfolio at
the American Association for Cancer Research (AACR) Annual Meeting
2021. Collectively, the planned data presentations will highlight
the potential of Blueprint Medicines' precision therapies to
deliver transformative benefits to broad patient populations with
systemic mastocytosis, non-small cell lung cancer and cyclin
E-aberrant cancers.
![blueprint_medicines_logo blueprint_medicines_logo](https://mma.prnewswire.com/media/221118/blueprint_medicines_logo.jpg)
"At the AACR annual meeting, we will present a wide range of
preclinical and clinical data that highlights our ability to
rapidly and reproducibly interrogate disease biology, design highly
selective and potent precision therapies, and advance clinical
development to address urgent patient needs," said Fouad Namouni,
M.D., President, Research & Development at Blueprint Medicines.
"Among multiple notable presentations, we plan to share for the
first time new preclinical data highlighting the potential of
BLU-701, a selective and potent double-mutant EGFR inhibitor, to
become a cornerstone of our efforts in lung cancer and the
potential of our research program targeting CDK2 to address a
variety of patient populations with cancers harboring primary or
acquired cyclin E aberrations."
Blueprint Medicines will host an investor conference call to
discuss the data presented at AACR, and will provide webcast timing
and dial-in information in advance of the meeting.
The accepted abstract titles are listed below and available on
the AACR conference website:
https://www.aacr.org/meeting/aacr-annual-meeting-2021/.
Oral Presentation
Presentation Title: PATHFINDER: Interim analysis of
avapritinib (ava) in patients (pts) with Advanced Systemic
Mastocytosis (AdvSM)
Session Title: Molecular Targeted Agents in the Clinic
Session Date & Time: Sunday,
April 11, 2021 from 2:00 – 4:00 p.m.
ET
Abstract Number: CT023
Poster Presentations
Presentation Title: BLU-701 is a highly potent,
brain-penetrant and WT-sparing next-generation EGFR TKI for the
treatment of sensitizing (ΔEx19, L858R) and C797S resistance
mutations in metastatic NSCLC
Session Title: Novel Antitumor Agents
Session Date & Time: Saturday,
April 10, 2021 at 8:30 a.m.
ET
Abstract Number: 1262
Presentation Title: BLU-945, a fourth-generation, potent
and highly selective epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) with intracranial activity,
demonstrates robust in vivo antitumor activity in models of
osimertinib-resistant non-small cell lung cancer (NSCLC)
Session Title: Tyrosine Kinase and Phosphatase Inhibitors
Session Date & Time: Saturday,
April 10, 2021 at 8:30 a.m.
ET
Abstract Number: 1467
Presentation Title: Development of a selective CDK2-E
inhibitor in CCNE driven cancers
Session Title: Novel Antitumor Agents
Session Date & Time: Saturday,
April 10, 2021 at 8:30 a.m.
ET
Abstract Number: 1279
Presentation Title: MAP4K1 inhibition enhances immune
cell activation and anti-tumor immunity in preclinical tumor
models
Session Title: Immunomodulatory Agents and Interventions
Session Date & Time: Saturday,
April 10, 2021 at 8:30 a.m.
ET
Abstract Number: 1717
Presentation Title: Changes in mast cell (MC) numbers and
phenotype in patients (pts) with indolent systemic mastocytosis
(ISM) treated with avapritinib
Session Title: Phase II Clinical Trials
Session Date & Time: Saturday,
April 10, 2021 at 8:30 a.m.
ET
Abstract Number: CT168
Presentation Title: Safety and pharmacokinetics of
BLU-263, a next-generation KIT inhibitor, in normal healthy
volunteers
Session Title: Phase I Clinical Trials
Session Date & Time: Saturday,
April 10, 2021 at 8:30 a.m.
ET
Abstract Number: CT122
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company
that invents life-changing medicines for people with cancer and
hematologic disorders. Applying an approach that is both precise
and agile, we create therapies that selectively target genetic
drivers, with the goal of staying one step ahead across stages of
disease. Since 2011, we have leveraged our research platform,
including expertise in molecular targeting and world-class drug
design capabilities, to rapidly and reproducibly translate science
into a broad pipeline of precision therapies. Today, we are
delivering our approved medicines to patients in the United
States and Europe, and we are globally advancing multiple
programs for genomically defined cancers, systemic mastocytosis,
and cancer immunotherapy. For more information,
visit www.BlueprintMedicines.com and follow us
on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding plans, strategies, timelines and expectations for
Blueprint Medicines' current or future approved drugs and drug
candidates, including the presentation of preclinical and clinical
data of such drugs and drug candidates; the potential benefits of
any of Blueprint Medicines' current or future approved drugs or
drug candidates in treating patients; and Blueprint Medicines'
strategy, goals and anticipated milestones, business plans and
focus. The words "aim," "may," "will," "could," "would," "should,"
"expect," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the impact of the
COVID-19 pandemic to Blueprint Medicines' business, operations,
strategy, goals and anticipated milestones, including Blueprint
Medicines' ongoing and planned research and discovery activities,
ability to conduct ongoing and planned clinical trials, clinical
supply of current or future drug candidates, commercial supply of
current or future approved products, and launching, marketing and
selling current or future approved products; Blueprint Medicines'
ability and plans in continuing to establish and expand a
commercial infrastructure, and successfully launching, marketing
and selling current or future approved products; Blueprint
Medicines' ability to successfully expand the approved indications
for AYVAKITTM/AYVAKYT® (avapritinib) and
GAVRETOTM (pralsetinib) or obtain marketing
approval for AYVAKIT/AYVAKYT in additional geographies in the
future; the delay of any current or planned clinical trials or the
development of Blueprint Medicines' current or future drug
candidates; Blueprint Medicines' advancement of multiple
early-stage efforts; Blueprint Medicines' ability to successfully
demonstrate the safety and efficacy of its drug candidates and gain
approval of its drug candidates on a timely basis, if at all; the
preclinical and clinical results for Blueprint Medicines' drug
candidates, which may not support further development of such drug
candidates; actions of regulatory agencies, which may affect the
initiation, timing and progress of clinical trials; Blueprint
Medicines' ability to obtain, maintain and enforce patent and other
intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or
any drug candidates it is developing; Blueprint Medicines' ability
to develop and commercialize companion diagnostic tests for
AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug
candidates; and the success of Blueprint Medicines' current and
future collaborations, partnerships or licensing arrangements.
These and other risks and uncertainties are described in greater
detail in the section entitled "Risk Factors" in Blueprint
Medicines' filings with the Securities and Exchange Commission
(SEC), including Blueprint Medicines' most recent Annual Report on
Form 10-K, as supplemented by its most recent Quarterly Report on
Form 10-Q and any other filings that Blueprint Medicines has made
or may make with the SEC in the future. Any forward-looking
statements contained in this press release represent Blueprint
Medicines' views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date.
Except as required by law, Blueprint Medicines explicitly disclaims
any obligation to update any forward-looking statements.
Trademarks
Blueprint Medicines, AYVAKIT/AYVAKYT, GAVRETO and associated
logos are trademarks of Blueprint Medicines Corporation.
View original
content:http://www.prnewswire.com/news-releases/blueprint-medicines-to-showcase-scientific-leadership-in-precision-oncology-and-hematology-at-aacr-annual-meeting-2021-301244983.html
SOURCE Blueprint Medicines Corporation